PMID- 6339850
OWN - NLM
STAT- MEDLINE
DCOM- 19830527
LR  - 20201209
IS  - 0023-852X (Print)
IS  - 0023-852X (Linking)
VI  - 93
IP  - 4
DP  - 1983 Apr
TI  - Immunobiologic staging of patients with carcinoma of the head and neck.
PG  - 445-63
AB  - For decades immunologic deficiencies have been documented in patients with 
      carcinoma, and many investigators have attempted to utilize this information in 
      determining prognosis more accurately. Determining prognosis more accurately 
      would be most helpful with Stage III patients, since at present there are no 
      useful guidelines as to which Stage III patients would benefit from aggressive 
      surgery and/or radiation therapy and which would not. Assays of cellular 
      immunity--such as skin testing, determining peripheral T-lymphocyte counts, and 
      assessing lymphocyte reactivity--have achieved extremely limited clinical 
      application. These assays are too expensive and/or too difficult to perform in 
      the routine clinical setting. Total lymphocyte counts, however, are readily 
      available in the clinical setting and can be helpful in determining prognosis. 
      Other readily available clinical information, such as age and pretreatment serum 
      immunoglobulin levels, can also be of value in determining prognosis. In this 
      study, logistic regression was utilized to determine the prognostic implications 
      of stage, age, and pretreatment total lymphocyte counts in 132 patients with 
      carcinoma of the head and neck. Although each variable determined prognosis 
      accurately less than 70% of the time, the stage, age, lymphocyte prognostic index 
      (SALPI) accurately predicted outcome at 3 year follow-up 80% of the time (Pr. 
      less than .0001). Discriminant function analysis was utilized to determine the 
      prognostic implications of pretreatment serum immunoglobulins in 243 patients 
      with head and neck carcinoma. A serum immunoglobulin prognostic index (SIPI) was 
      derived which was based on the observations that elevated levels of 
      immunoglobulin A (IgA) indicated a poor prognosis, while elevated levels of 
      immunoglobulin E (IgE) and immunoglobulin D (IgD) indicated a favorable prognosis 
      (Pr. less than .009). The SIPI was not as accurate as the SALPI in determining 
      prognosis; however, when the indices were used simultaneously, concurring indices 
      predicted the outcome of Stage III patients correctly 86% of the time.
FAU - Katz, A E
AU  - Katz AE
LA  - eng
GR  - 5T01NS 0511617/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PT  - Review
PL  - United States
TA  - Laryngoscope
JT  - The Laryngoscope
JID - 8607378
RN  - 0 (Dinitrochlorobenzene)
RN  - 0 (Immunoglobulin A)
RN  - 0 (Immunoglobulin D)
RN  - 0 (Immunoglobulins)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - Adult
MH  - Age Factors
MH  - Aged
MH  - Antibody Formation
MH  - Dinitrochlorobenzene
MH  - Female
MH  - Head and Neck Neoplasms/immunology/*pathology
MH  - Humans
MH  - Immunoglobulin A/analysis
MH  - Immunoglobulin D/analysis
MH  - Immunoglobulin E/analysis
MH  - Immunoglobulins/analysis
MH  - Leukocyte Count
MH  - Lymphocyte Activation
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging/*methods
MH  - Prognosis
MH  - Retrospective Studies
MH  - Skin Tests
MH  - Statistics as Topic
MH  - Tuberculin Test
RF  - 270
EDAT- 1983/04/01 00:00
MHDA- 1983/04/01 00:01
CRDT- 1983/04/01 00:00
PHST- 1983/04/01 00:00 [pubmed]
PHST- 1983/04/01 00:01 [medline]
PHST- 1983/04/01 00:00 [entrez]
AID - 10.1002/lary.1983.93.4.445 [doi]
PST - ppublish
SO  - Laryngoscope. 1983 Apr;93(4):445-63. doi: 10.1002/lary.1983.93.4.445.